BACKGROUND: Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. DESIGN AND METHODS: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. RESULTS: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. CONCLUSIONS: Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia.
BACKGROUND:Imatinib mesylate is the first line treatment for chronic myeloid leukemia. The advent of imatinib increased survival significantly in patients in an advanced phase of the disease. However, few long-term data on the outcome of these patients based on large, prospective and controlled trials are available. DESIGN AND METHODS: A phase 2 multicenter trial of the use of imatinib 600 mg/daily in patients with accelerated phase chronic myeloid leukemia was sponsored and promoted by the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 2001. RESULTS: One hundred and eleven patients were enrolled; the median follow-up of the 41 living patients is 82 months (range, 73-87). One hundred and seven patients (96%) returned to chronic phase and 79 patients (71%) achieved a complete hematologic response. Cumulative best rates of major cytogenetic response and complete cytogenetic response were 30% and 21%, respectively. All responses were maintained for a minimum of 4 weeks. At last follow-up, four patients were alive in complete remission after allogeneic transplant, 16 patients (14%) had switched to a second generation tyrosine kinase inhibitor and 21 patients (19%) were alive on imatinib therapy. No late toxicities were observed. Progression-free survival and event-free survival rates were 36.5% and 15%, respectively, at 7 years. The median survival time was 37 months, and was significantly associated with the achievement of a complete hematologic response or a complete cytogenetic response. CONCLUSIONS:Imatinib may induce durable responses, associated with prolonged survival, in patients with accelerated phase chronic myeloid leukemia.
Authors: S Sacchi; H M Kantarjian; S O'Brien; J Cortes; M B Rios; F J Giles; M Beran; C A Koller; M J Keating; M Talpaz Journal: Cancer Date: 1999-12-15 Impact factor: 6.860
Authors: Charles L Sawyers; Andreas Hochhaus; Eric Feldman; John M Goldman; Carole B Miller; Oliver G Ottmann; Charles A Schiffer; Moshe Talpaz; Francois Guilhot; Michael W N Deininger; Thomas Fischer; Steve G O'Brien; Richard M Stone; Carlo B Gambacorti-Passerini; Nigel H Russell; Jose J Reiffers; Thomas C Shea; Bernard Chapuis; Steven Coutre; Sante Tura; Enrica Morra; Richard A Larson; Alan Saven; Christian Peschel; Alois Gratwohl; Franco Mandelli; Monique Ben-Am; Insa Gathmann; Renaud Capdeville; Ronald L Paquette; Brian J Druker Journal: Blood Date: 2002-05-15 Impact factor: 22.113
Authors: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: Anna Sureda; Marina Carrasco; Miguel de Miguel; Jesùs A Martínez; Eulogio Conde; Miguel A Sanz; Joaquin Díaz-Mediavilla; Jorge Sierra Journal: Haematologica Date: 2003-11 Impact factor: 9.941
Authors: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Terry L Smith; Mary Beth Rios; Jianqin Shan; Ying Yang; Francis J Giles; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; William Wierda; Jean-Pierre J Issa; Steven M Kornblau; Michael Keating; Debra Resta; Renaud Capdeville; Moshe Talpaz Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: P Kongtim; K Adekola; D R Milton; R Ramlal; A Jimenez; J Chen; G Rondon; S Ahmed; P Kebriaei; O Betul; C M Hosing; U Popat; I Khouri; E Jabbour; J E Cortes; H M Kantarjian; R E Champlin; S O Ciurea Journal: Leukemia Date: 2017-04-12 Impact factor: 11.528
Authors: Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi Journal: Am J Hematol Date: 2011-09 Impact factor: 10.047